ASMB
Assembly Biosciences, Inc.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
1.58
P/S
6.41
EV/EBITDA
-39.57
DCF Value
$-64.83
FCF Yield
-8.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
77.7%
Operating Margin
-16.8%
Net Margin
-8.5%
ROE
-5.6%
ROA
-2.4%
ROIC
-5.8%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $42.5M | $22.1M | $2.49 |
| FY 2025 | $72.3M | $-6.1M | $-0.55 |
| Q3 2025 | $10.8M | $-9.2M | $-1.20 |
| Q2 2025 | $9.6M | $-10.2M | $-1.33 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
1.16
Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection. It is also developing ABI-H3733 that has completed Phase 1a clinical study, and ABI-4334, which is in pre-clinical trials for the treatment of HBV. The company has collaboration agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation; and Antios Therapeutics, Inc. to evaluate a triple combination treatment in patients with chronic hepatitis B virus infection. It also has strategic license agreements with Indiana University Research and Technology Corporation; and Door Pharmaceuticals, LLC. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.